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Transient receptor potential vanilloid 4 (TRPV4) has been reported to be responsible
for neuronal injury in pathological conditions. Excessive oxidative stress can lead
to neuronal damage, and activation of TRPV4 increases the production of reactive
oxygen species (ROS) and nitric oxide (NO) in many types of cells. The present
study explored whether TRPV4-induced neuronal injury is mediated through enhancing
oxidative stress. We found that intracerebroventricular injection of the TRPV4 agonist
GSK1016790A increased the content of methane dicarboxylic aldehyde (MDA) and
NO in the hippocampus, which was blocked by administration of the TRPV4 specific
antagonist HC-067047. The activities of catalase (CAT) and glutathione peroxidase
(GSH-Px) were decreased by GSK1016790A, whereas the activity of superoxide
dismutase (SOD) remained unchanged. Moreover, the protein level and activity of
neuronal nitric oxide synthase (nNOS) were increased by GSK1016790A, and the
GSK1016790A-induced increase in NO content was blocked by an nNOS specific
antagonist ARL-17477. The GSK1016790A-induced modulations of CAT, GSH-Px and
nNOS activities and the protein level of nNOS were significantly inhibited by HC-067047.
Finally, GSK1016790A-induced neuronal death and apoptosis in the hippocampal CA1
area were markedly attenuated by administration of a ROS scavenger Trolox or ARL-
17477. We conclude that activation of TRPV4 enhances oxidative stress by inhibiting
CAT and GSH-Px and increasing nNOS, which is responsible, at least in part, for TRPV4-
induced neurotoxicity.
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INTRODUCTION
Oxidative stress is a state of imbalance between the level of the antioxidant defense mechanisms
and the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS;
Simonian and Coyle, 1996). ROS mainly include superoxide anions, hydroxyl radicals
and hydrogen peroxide (H2O2), and the major RNS include nitric oxide (NO), nitrogen
dioxide and peroxynitrite (Bhat et al., 2015). Enzymatic and nonenzymatic antioxidants are
cellular defense mechanisms that reduce the steady-state concentrations of ROS and RNS
and repair oxidative cellular damage (Simonian and Coyle, 1996). Overproduction of free
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radicals can lead to necrotic cell damage and mediates
apoptosis induced by a variety of stimuli (Loh et al., 2006).
Growing evidence shows that oxidative stress is involved
in mediating neuronal injury in diseases such as cerebral
ischemia, Alzheimer’s disease (AD) and Parkinson’s disease
(PD; Loh et al., 2006; Bhat et al., 2015). It has been
shown that free radical production might be linked to a
loss of cellular calcium (Ca2+) homeostasis and that Ca2+
overload is detrimental to mitochondrial function, leading
to the generation of ROS in the mitochondria (Ermak and
Davies, 2002). In the central nervous system (CNS), the
expression of neuronal nitric oxide synthase (nNOS) accounts
for the majority of NO activity, and increased intracellular
Ca2+ levels can induce the production of NO through the
stimulation of nNOS (Zhou and Zhu, 2009). Conversely,
reciprocal interactions occur between Ca2+ and oxidative stress,
which are involved in cellular damage (Ermak and Davies, 2002;
Chinopoulos and Adam-Vizi, 2006; Kiselyov and Muallem,
2016).
The transient receptor potential (TRP) protein superfamily
is a diverse group of Ca2+-permeable cation channels that
are expressed in mammalian cells. Transient receptor potential
vanilloid 4 (TRPV4) is a member of the TRP superfamily
(Benemei et al., 2015). Activation of TRPV4 induces Ca2+
influx and increases the intracellular concentration of free
Ca2+ ([Ca2+]i). Recent studies have reported that application
of a TRPV4 agonist enhances the production of ROS in
cultured human coronary artery endothelial cells and human
coronary arterioles, which is dependent on TRPV4-mediated
increases in [Ca2+]i (Bubolz et al., 2012). Activation of
TRPV4 elicits Ca2+ signal and stimulates H2O2 production
in urothelial cells (Donkó et al., 2010). TRPV4 agonists
significantly increase intracellular Ca2+ level and the production
of superoxide in lung macrophages (Hamanaka et al., 2010).
Ca2+ influx mediates the TRPV4-induced production of NO
in the dorsal root ganglion following chronic compression
and in the outer hair cells (Takeda-Nakazawa et al., 2007;
Wang et al., 2015). These reports indicate that activation
of TRPV4 may increase the production of ROS and RNS.
TRPV4-induced toxicity has been confirmed in several types
of cells, and activation of TRPV4 is responsible for neuronal
injury in pathological conditions such as cerebral ischemic
injury and AD (Li et al., 2013; Bai and Lipski, 2014; Jie
et al., 2015, 2016). In our recent studies, intracerebroventricular
injection of a TRPV4 agonist induced neuronal death in
the hippocampus (Jie et al., 2015, 2016). In the present
study, we investigated the effects of TRPV4 activation on
oxidative stress in the hippocampus and further explored
the involvement of this action in TRPV4-induced neuronal
injury.
MATERIALS AND METHODS
Animals
Male mice (9–10 weeks old, ICR, Oriental Bio Service Inc.,
Nanjing, China) were used. All experimental procedures
conformed to the Guidelines for Laboratory Animal Research
of Nanjing Medical University and were approved by the
Institutional Animal Care and Use Committee of Nanjing
Medical University.
Drug Treatment
Drugs were intracerebroventricularly (icv.) injected as previously
reported (Jie et al., 2016). Mice were anesthetized and placed
in a stereotaxic device (Kopf Instruments, Tujunga, CA,
USA). Drugs were injected into the right lateral ventricle
(0.3 mm posterior, 1.0 mm lateral and 2.5 mm ventral to
bregma) using a stepper-motorized micro-syringe (Stoelting,
Wood Dale, IL, USA). GSK1016790A, HC-067047 and
Trolox were first dissolved in DMSO and then in 0.9%
saline to a final volume of 2 µl with a DMSO concentration
of 1%. GSK1016790A is a specific agonist of TRPV4 and
HC-067047 is a specific antagonist of it (Vincent and Duncton,
2011). GSK1016790A (0.1–5 µM/mouse) was injected once.
HC-067047 was injected 30 min before the GSK1016790A
injection and subsequently injected every 8 h for 3 days.
ARL-17477 is a selective nNOS inhibitor and Trolox is a ROS
scavenger (Zhang et al., 1996; Fang et al., 2013). ARL-17477
(1 µM/mouse) and Trolox (150 µM/mouse) were injected
30 min before the GSK1016790A injection and then injected
once daily for 3 days. The doses of the drugs listed above
were chosen according to previous reports (Zhang et al.,
1996; Fang et al., 2013; Jie et al., 2016). Mice were randomly
divided into the following groups: GSK1016790A group
(mice were injected with GSK1016790A, GSK1016790A-
injected mice), HC-067047 group (mice were injected with
HC-067047), ARL-17477 group (mice were injected with
ARL-17477), Trolox group (mice were injected with Trolox),
GSK1016790A+HC-067047 group (mice were co-injected
with GSK1016790A and HC-067047), GSK1016790A+ARL-
17477 group (mice were co-injected with GSK1016790A
and ARL-17477), GSK1016790A+Trolox group (mice were
co-injected with GSK1016790A and Trolox) and control
group (mice were injected with the same volume of the
vehicle). In the following experiments, each group contained
nine mice.
Histological Examination
Histological examination of the hippocampal CA1 region
was performed 3 days after the GSK1016790A injection.
Mice were anesthetized and transcardially perfused with
ice-cold phosphate-buffered saline (PBS) followed by 4%
paraformaldehyde. After the brains were removed, they
were placed in fixative at 4◦C overnight and processed
for paraffin embedding. Coronal sections (5 µm) were cut
from the level of the hippocampus and used for toluidine
blue or Hoechst staining. For toluidine blue staining,
the pyramidal cells were identified using a conventional
light microscope (Olympus DP70, Olympus, Tokyo,
Japan) with a 40× objective. For Hoechst staining, the
slices were stained with Hoechst-33342, and Hoechst-
positive (Hoechst+) cells were counted using a fluorescence
microscope (Olympus PD70, Olympus, Tokyo, Japan) with a
40× objective.
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The neurons survived or Hoechst+ cells were counted in
six sections per mouse, and the density was expressed as the
number of cells per millimeter of length along the hippocampal
CA1 pyramidal layer (Jie et al., 2015, 2016). The density of
the surviving neurons or Hoechst+ cells in mice injected with
GSK1016790A or GSK1016790A and Trolox/ARL-17477 was
expressed as a percentage of the corresponding cells in the
control mice.
Western Blot Analysis
Western blot analysis was performed 3 days after the
GSK1016790A injection as previously reported (Li et al.,
2013; Jie et al., 2016). In brief, the hippocampi were collected
and homogenized in a lysis buffer containing 50 mM Tris-
HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 10 mM NaF,
1 mM sodium orthovanadate, 1% Triton X-100, 0.5% sodium
deoxycholate, 1 mM phenylmethylsulfonyl fluoride and a
protease inhibitor cocktail (Complete; Roche, Mannheim,
Germany). Protein concentrations were determined using a
Bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rochford,
IL, USA). Total proteins were separated using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
were then transferred to a polyvinylidene difluoride (PVDF)
membrane. The membranes were incubated with 5% nonfat
dried milk in Tris-buffered saline containing 0.1% Tween 20
(TBST) for 60 min at room temperature and were then incubated
with primary antibodies against nNOS (1:1000, Cell Signaling
Technology, Boston,MA, USA) and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; 1:5000, Abcam, Cambridge, MA,
USA). Hippocampal samples were collected from the hemisphere
of three mice as a set of western blot analysis. The summarized
data represent the average of three experimental sets.
nNOS Activity Assay
The activity of nNOS was measured 3 days after the
GSK1016790A injection using a commercially available kit
(Calbiochem, San Diego, CA, USA) according to previously
reported methods (Zhu et al., 2016). The activity of nNOS
was calculated by subtracting the activity of inducible NOS
(iNOS) from the total NOS activity with the inhibited fraction
of endothelial NOS (eNOS). The activity of nNOS in the
GSK1016790A-injected mice was normalized to the activity in
the control mice.
Enzyme-Linked Immunosorbent Assay
(ELISA)
Enzyme-Linked Immunosorbent Assays (ELISA) were
performed 3 days after the GSK1016790A injection as previously
reported (Li et al., 2010). The content of methane dicarboxylic
aldehyde (MDA) and NO, and the activity of catalase (CAT),
superoxide dismutase (SOD) and glutathione peroxidase (GSH-
Px) in the hippocampal homogenates were determined using an
ELISA according to the manufacturer’s instructions (Nanjing
Jiancheng Biochemistry Co., Nanjing, China), and the content
or activity in the mice injected with GSK1016790A and/or
antagonist was normalized to the control values.
Chemicals
All chemicals, unless otherwise stated, were obtained from Sigma
Chemical Company.
Data Analysis
Data are expressed as mean ± S.E.M and were analyzed using
Stata 7.0 software (STATA Corporation, USA). The statistical
analysis was conducted using analysis of variance (ANOVA)
followed by Bonferroni’s post hoc test, and significance levels
were set at P < 0.05 and P < 0.01. The dose-response curve
was fit using the Hill equation in which a= amax/[1+(EC50/C)n],
with n being the Hill coefficient and EC50 being the dose of
GSK1016790A that produced a 50% effect.
RESULTS
Effect of the TRPV4 Agonist GSK1016790A
on the MDA and NO Content in the
Hippocampus
In this study, GSK1016790A was used to explore the effect
of TRPV4 activation on oxidative stress in the hippocampus.
Lipid peroxidation in the hippocampus was assessed by detecting
the MDA content. As shown in Figure 1A, the MDA content
was significantly increased in the GSK1016790A-injected mice
compared to the control mice (P < 0.01). The GSK1016790A-
induced increase in the MDA content was dose-dependent at
doses ranging from 0.1 µM/mouse to 5 µM/mouse, and the
EC50 value was 0.63 ± 0.14 µM/mouse (Figure 1B). Meanwhile,
the NO content was higher in the GSK1016790A-injected
mice than that in the control mice (P < 0.01; Figure 1C).
As shown in Figure 1D, the GSK1016790A-induced increase
in the NO content was also dose-dependent, and the EC50
value was 0.69 ± 0.04 µM/mouse at doses of GSK1016790A
ranging from 0.1 µM/mouse to 5 µM/mouse. These results
indicate that application of a TRPV4 agonist may increase
the generation of ROS and NO. Because GSK1016790A at
the dose of 1 µM/mouse caused a significant increase in the
MDA (343.77 ± 27.79%) and NO content (188.17 ± 10.10%),
and this dose of GSK1016790A has been shown to induce
neurotoxicity in previous studies (Jie et al., 2015, 2016),
GSK1016790A at the dose of 1 µM/mouse was used in the
following experiments.
Effect of GSK1016790A on the Activity of
Antioxidant Enzymes and the Protein Level
and Activity of nNOS in the Hippocampus
Antioxidant enzymes responsible for endogenous defense
include GSH-Px, CAT and SOD. As shown in Figure 2A, the
activities of CAT and GSH-Px were significantly lower in the
GSK1016790A-injected mice (CAT: 12.07 ± 3.62%, GSH-Px:
66.55 ± 7.15%, P < 0.01), whereas the activity of SOD was
unchanged, which implies that CAT and GSH-Px are selectively
inhibited by the TRPV4 agonist.
In addition, the protein level and activity of nNOS were
significantly increased in the GSK1016790A-injected mice
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FIGURE 1 | Effect of the Transient receptor potential vanilloid 4 (TRPV4) agonist GSK1016790A on methane dicarboxylic aldehyde (MDA) and nitric
oxide (NO) content. (A,B) The MDA content in the hippocampus was increased in a dose-dependent manner by the application of the TRPV4 agonist
GSK1016790A (0.1–5 µM/mouse), and the EC50 and n values of the dose-response curve were 0.63 ± 0.14 µM/mouse and 1.40, respectively. (C,D) The NO
content in the hippocampus was increased by injection of GSK1016790A (0.1–5 µM/mouse) in a dose-dependent manner, and the EC50 and n values of the
dose-response curve were 0.69 ± 0.04 µM/mouse and 1.33, respectively. ∗∗P < 0.01 vs. control.
(Figures 2B,C; P < 0.01). We also found that the increased
NO content in the GSK1016790A-injected mice was attenuated
by application of ARL-17477 which is an nNOS specific
inhibitor (Figure 2D; P < 0.01). These results indicate that
application of a TRPV4 agonist enhances NO production,
which is likely mediated through increasing nNOS activity and
expression.
Effect of Administration of a TRPV4
Antagonist on the GSK1016790A-Induced
Changes in the MDA and NO Content,
Activity of Antioxidant Enzymes and
Expression and Activity of nNOS
The TRPV4 specific antagonist HC-067047 (10 µM/mouse)
was used to further confirm the role of TRPV4 in the above
GSK1016790A-induced actions. As shown in Figures 3A,B,
the MDA and NO content was significantly decreased in
the mice co-injected with GSK1016790A and HC-067047
(MDA: 108.45 ± 10.41%, NO: 109.00 ± 7.01%) compared to
GSK1016790A-injected mice (P < 0.01). Figure 3C shows that
the activities of CAT and GSH-Px in the mice co-injected
with GSK1016790A and HC-067047 were significantly increased
(CAT: 99.07 ± 1.14%, GSH-Px: 98.55 ± 4.15%) compared
to GSK1016790A-injected mice (P < 0.01). Moreover, the
increase in both the protein level and activity of nNOS in the
GSK1016790A-injected mice were significantly blocked by HC-
067047 (P < 0.01; Figure 3D). Collectively, the present results
indicate that activation of TRPV4 may enhance oxidative stress,
which may be mediated through inhibiting CAT and GSH-Px,
and enhancing nNOS expression and activity.
Effect of Administration of a ROS
Scavenger and an nNOS Inhibitor on
TRPV4 Agonist-Induced Neuronal Injury
In the present study, the densities of the surviving neurons
and Hoechst+ cells in the control group were 327 ± 15.64/mm
and 4.14 ± 1.93/mm, respectively, which were consistent
with previous reports (Jie et al., 2015, 2016). Activation of
TRPV4 has been shown to induce toxicity. As shown in
Figure 4A, the number of surviving cells was decreased by
GSK1016790A treatment (GSK1016790A: 61.07 ± 2.03%), and
more surviving neurons were found in the GSK1016790A-
injected mice when they were co-injected with the ROS
scavenger Trolox (GSK1016790A+Trolox: 85.78 ± 5.18%) or
with ARL-17477 (GSK1016790A+ARL-17477: 75.13 ± 3.14%;
P < 0.01). Additionally, more Hoechst+ cells were found
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FIGURE 2 | Effect of GSK1016790A on the antioxidant enzyme activity and neuronal nitric oxide synthase (nNOS) protein level and activity. (A) The
activities of catalase (CAT) and glutathione peroxidase (GSH-Px) were reduced by GSK1016790A, whereas superoxide dismutase (SOD) activity was unaffected.
(B,C) The protein level (B) and activity (C) of nNOS were increased by GSK1016790A. (D) The NO content in the hippocampus was increased by injection of
GSK1016790A, which was significantly blocked by the nNOS inhibitor ARL-17477. ∗P < 0.05 and ∗∗P < 0.01 vs. control, ##P < 0.01 vs. GSK1016790A.
FIGURE 3 | Effect of the TRPV4 specific antagonist HC-067047 on the GSK1016790A-induced modulations of the MDA and NO content, CAT and
GSH-Px activities and nNOS protein level and activity. (A,B) HC-067047 had no effect on the MDA or NO content in the control mice, but significantly blocked
the increase in MDA (A) and NO (B) content in the GSK1016790A-injected mice. (C) The GSK1016790A-induced decrease in CAT and GSH-Px activities was
significantly blocked by HC-067047. (D) The increase in both the protein level and activity of nNOS in the GSK1016790A-injected mice was significantly attenuated
by HC-067047. ∗∗P < 0.01 vs. control, ##P < 0.01 vs. GSK1016790A.
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FIGURE 4 | Effect of a reactive oxygen species (ROS) scavenger and an nNOS inhibitor on GSK1016790A-induced neuronal injury. (A) Injection of the
TRPV4 agonist GSK1016790A reduced the number of surviving cells in the hippocampal CA1 area, which was significantly attenuated by the ROS scavenger Trolox
and the nNOS inhibitor ARL-17477. Scale bar = 50 µM. (B) More Hoechst+ cells (white stars) were found in the hippocampal CA1 area in the
GSK1016790A-injected mice, which was markedly blocked by Trolox and ARL-17477. Scale bar = 50 µM. ∗∗P < 0.01 vs. control, ##P < 0.01 vs. GSK1016790A.
in the GSK1016790-injected mice (183.07 ± 10.03%), which
was significantly attenuated by administration of Trolox
(135.90 ± 11.052%) or ARL-17477 (145.01 ± 9.14%; P < 0.01;
Figure 4B). These results indicate that enhanced oxidative stress
is responsible, at least in part, for the TPPV4 activation-induced
neurotoxicity.
DISCUSSION
TRPV4 is widely expressed in the nervous system and is normally
assembled as a homotetramer. TRPV4 can also be assembled
as a heterotetramer (e.g., with TRPC1 in vascular endothelial
cells, TRPP2 in tsA 201 cells and a heteromeric TRPV4-TRPC1-
TRPP2 complex in primary cultured rat mesenteric artery
endothelial cells and cotransfected HEK293 cells; Stewart et al.,
2010;Ma et al., 2011; Du et al., 2014). However, it is still unknown
whether these heterotetramers exist in the CNS. TRPV4 is
sensitive to multiple stimuli including physical factors (e.g.,
hypotonicity-induced cell swelling, mild heat and mechanical
stimulation), endogenous stimuli (e.g., arachidonic acid (AA)
and its metabolites including epoxyeicosatrienoic acids) and
synthetic chemicals (e.g., GSK1016790A and 4α-PDD; Vincent
and Duncton, 2011). Increasing evidence suggests that activation
of TRPV4 is involved in the pathogenesis of some nervous
system diseases and is responsible for neuronal injury. For
example, TRPV4 protein levels are up-regulated during cerebral
ischemia, and inhibition of TRPV4 reduces brain infarction
(Li et al., 2013; Jie et al., 2016). TRPV4 immunoreactivity
is significantly increased in the cerebral cortex, hippocampal
formation, striatum and thalamus in a mouse model of AD
(Lee and Choe, 2016). β-amyloid peptide-1–40 (Aβ1–40) can
activate astrocytic TRPV4 in the hippocampus, and TRPV4
antagonists reduce neuronal and astrocytic damage caused by
Aβ1–40 (Bai and Lipski, 2014). Because TRPV4 is permeable
to Ca2+, its activation induces Ca2+ influx (Benemei et al.,
2015). Therefore, TRPV4-induced elevations in [Ca2+]i have
attracted significant attention in research aimed at exploring the
mechanisms underlying TRPV4-mediated neuronal injury.
Oxidative stress refers to the cytopathological consequences
of a mismatch between the production and elimination of free
radicals and has been confirmed to be responsible for neuronal
injury in pathological conditions (Simonian and Coyle, 1996;
Loh et al., 2006; Bhat et al., 2015). Increased [Ca2+]i can initiate
a number of deleterious processes including activation of NOS
and free radical generation (Ermak and Davies, 2002). Recent
studies have reported that activation of TRPV4 enhances the
production of ROS or NO in endothelial cells, urothelial cells,
macrophages and outer hair cells, which is related to TRPV4-
mediated Ca2+ signaling (Takeda-Nakazawa et al., 2007; Donkó
et al., 2010; Hamanaka et al., 2010; Bubolz et al., 2012;Wang et al.,
2015). Consistent with these results, the present study showed
that application of the TRPV4 agonist GSK1016790A increased
the MDA and NO content in the hippocampus (Figure 1). It has
been reported that activation of N-Methyl-D-Aspartate (NMDA)
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glutamate receptors results in increased nNOS-mediated NO
generation (Yamada andNabeshima, 1997). In the hippocampus,
activation of TRPV4 enhances NMDA receptor-mediated Ca2+
influx (Li et al., 2013), which may contribute to TRPV4-
induced increases in [Ca2+]i and the production of free radicals.
NO is derived from three isoforms of NOS (nNOS, eNOS
and iNOS), of which nNOS and iNOS have been reported
to be involved in neuronal injury during the early and late
stages of cerebral ischemia, respectively (Zhang et al., 1996;
ArunaDevi et al., 2010). In this study, we found that the protein
level and activity of nNOS were increased by treatment with
GSK1016790A (Figures 2B,C), and an nNOS specific inhibitor
ARL-17477 blocked the GSK1016790A-induced increase in NO
content (Figure 2D), which indicated that application of the
TRPV4 agonist may enhance nNOS resulting in increased NO
production. The present study also showed that the activities of
CAT and GSH-Px were selectively reduced by GSK1016790A
(Figure 2A). It was also noted that the GSK1016790A-induced
increase in MDA and NO content was significantly blocked
by the TRPV4 specific antagonist HC-067047. In addition, the
GSK1016790A-induced increase in nNOS protein level and
activity and the inhibition of CAT and GSH-Px activities were
significantly blocked by HC-067047 (Figure 3). These results
further confirmed that activation of TRPV4 might enhance
oxidative stress in the hippocampus, which may be a result of
increased free radicals production and decreased elimination of
free radicals.
It has been shown that inhibition of TRPV4 increases
the viability of astrocytes following an oxidative stress insult
(Bai and Lipski, 2010). TRPV4 contributes to Aβ1–40-induced
neuronal and astrocytic damage, which is related to oxidative
stress (Bai and Lipski, 2014). We recently reported TRPV4-
induced neurotoxicity in vivo (Jie et al., 2015, 2016). Here,
GSK1016790A-induced neuronal loss and apoptosis in the
hippocampal CA1 area were significantly blocked by a ROS
scavenger and an nNOS specific inhibitor, which indicated that
the TRPV4-induced neurotoxicity was mediated, at least in part,
through enhanced oxidative stress (Figure 4). Our unpublished
data show that inhibition of TRPV4 reduces infarction in a
myocardial ischemia-reperfusion model through inhibition of
ROS production (Du and Chen, unpublished data). Although
differentmechanisms underlie cerebral andmyocardial ischemia,
excessive oxidative stress plays an important role in both
neuronal and myocardial injury. Therefore, it is proposed
that TRPV4-mediated enhancement of oxidative stress is likely
responsible for the neuronal injury in cerebral ischemia injury;
however, this hypothesis should be further confirmed.
The present study showed that enhanced oxidative stress
was involved in TRPV4-induced hippocampal neuronal injury.
Conversely, some TRP channels can potentially act as sensors
of changes in the cellular redox status and contribute to ROS-
induced increases in intracellular Ca2+ concentrations (Badr
et al., 2016; Ogawa et al., 2016). It has been reported that TRPV4
can be activated by NO and H2O2 (Yoshida et al., 2006; Badr
et al., 2016). Therefore, it is possible that TRPV4 and free radicals
may form a positive feedback loop that is involved in neuronal
injury under pathological conditions. Combined with previous
reports, this study indicates that targeting TRPV4 might be a
potential strategy for neuronal protection.
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